{"commentary":{"count":22,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":15,"podcast":6,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05215340\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"TROPION-Lung08","nct_id":"NCT05215340","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tropion-lung08-nct05215340. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"TROPION-Lung08","arms":[{"description":"Participants will be randomized to receive 200 mg pembrolizumab followed by 6.0mg/kg Dato-DXd.","label":"Pembrolizumab + Datopotamab Deruxtecan (Dato-DXd)","type":"EXPERIMENTAL"},{"description":"Participants will be randomized to receive 200 mg pembrolizumab.","label":"Pembrolizumb","type":"ACTIVE_COMPARATOR"}],"collaborators":["AstraZeneca","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2032-03-04","type":"ESTIMATED"},"conditions":["Metastatic Non Small Cell Lung Cancer"],"enrollment":{"count":740,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Datopotamab Deruxtecan","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"}],"last_update":"2026-09-24","lead_sponsor":"Daiichi Sankyo","official_title":"A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-03-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival Based on Blinded Independent Central Review in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab","timeFrame":"From randomization until disease progression or death (whichever occurs first), up to approximately 46 months"},{"measure":"Overall Survival (OS) in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab","timeFrame":"From randomization until date of death due to any cause, up to approximately 72 months"}],"references":[{"citation":"Levy BP, Felip E, Reck M, Yang JC, Cappuzzo F, Yoneshima Y, Zhou C, Rawat S, Xie J, Basak P, Xu L, Sands J. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol. 2023 Jul;19(21):1461-1472. doi: 10.2217/fon-2023-0230. Epub 2023 May 30.","pmid":"37249038","type":"DERIVED"}],"start_date":{"date":"2022-03-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations","url":"https://clinicaltrials.gov/study/NCT05215340"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tropion-lung08-nct05215340"}